

8. (Amended) The composition of claim 1, wherein the amino acid sequence of the peptide comprises Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Xaa (SEQ ID No: 13), wherein Xaa is not a methionine residue.

10. (Amended) The composition of claim 1, having at least one dextrorotatory amino acid.

A² concl. 11. (Amended) A composition comprising a substance P peptide in a dose effective to inhibit growth of a fungal cell.

12. (Amended) The composition of claim 1, wherein the cell is selected from the genera consisting of *Staphylococcus*, *Streptococcus*, *Bacillus*, *Clostridium*, *Escherichia*, *Shigella*, *Campylobacter*, *Hemophilus*, *Proteus*, *Yersinia*, *Klebsiella*, *Pseudomonas*, and *Serratia*.

13. (Amended) The composition of claim 11, wherein the cell is selected from the genera consisting of *Aspergillus*, *Candida*, *Cryptococcus*, *Epidermophyton*, *Histoplasma*, *Microsporum*, and *Trichophyton*.

14. (Amended) The composition of claim 1, further comprising a second antibacterial agent.

A³ 24. (Amended) A kit comprising for treating a bacterial or fungal infection comprising at least one unit dose of a substance P peptide as shown in SEQ ID Nos: 1 or 2 in a physiologically acceptable carrier, wherein said dose is effective to inhibit growth of a bacterial or a fungal cell, the kit further comprising a label and instructions for use.

Please add new claims 25-46 as follows:

A⁴ 25. (NEW) The composition of claim 11, wherein the amino acid sequence of the peptide comprises residues of 1-8 of SEQ ID No: 2.

26. (NEW) The composition of claim 11, wherein the amino acid sequence of the peptide comprises amino acids 1-10 of SEQ ID Nos: 1 or 2.

27. (NEW) The composition of claim 11, having at least one dextrorotatory amino acid.

28. (NEW) The composition of claim 11, further comprising a second anti-fungal agent.

29. (NEW) The composition of claim 1, adapted for topical administration.

30. (NEW) The composition of claim 11, adapted for topical administration.

31. (NEW) A composition comprising a fragment of a substance P peptide, wherein said fragment comprises antimicrobial activity and does not bind to a cell surface substance P peptide receptor.

32. (NEW) A composition of claim 31, wherein the antimicrobial activity inhibits growth of a bacterial cell.

33. (NEW) A composition of claim 31, wherein the antimicrobial activity inhibits growth of a fungal cell.

34. (NEW) A composition of claim 31 comprising residues 1-8 of SEQ ID No.: 1.

35. (NEW) A composition of claim 31 comprising residues 1-8 of SEQ ID No.: 2.

36. (NEW) A composition of claim 31 comprising residues 1-9 of SEQ ID No.: 1.

37. (NEW) A composition of claim 31 comprising residues 1-9 of SEQ ID No.: 2.

38. (NEW) A composition of claim 31 comprising residues 1-10 of SEQ ID No.: 1.

39. (NEW) A composition of claim 31 comprising residues 1-10 of SEQ ID No.: 2.

40. (NEW) The composition of claim 1, wherein said dose comprises at least 44 μ M substance P peptide.

41. (NEW) The composition of claim 1, wherein said dose comprises about 44 μ M to about 10 mM substance P peptide.